09.08.2014 Views

JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL

During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.

See More: http://goo.gl/tW6DQL

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Table 16: UCDAI 83<br />

Table 17: Treatment Guidelines for UC Used in the 10MM 84<br />

Table 18: Most Commonly Prescribed <strong>Drug</strong>s for UC by Class in the 10MM, 2013 85<br />

Table 19: UC Management Country Profile - US 91<br />

Table 20: UC Management Country Profile - France 93<br />

Table 21: UC Management Country Profile - Germany 95<br />

Table 22: UC Management Country Profile - Italy 97<br />

Table 23: UC Management Country Profile - Spain 98<br />

Table 24: UC Management Country Profile - UK 101<br />

Table 25: UC Management Country Profile - Japan 103<br />

Table 26: Country Profile - Canada 105<br />

Table 27: UC Management Country Profile - China 107<br />

Table 28: UC Management Country Profile - India 109<br />

Table 29: Leading Treatments for UC, 2014 112<br />

Table 30: Product Profile - Remicade 115<br />

Table 31: Remicade SWOT <strong>Analysis</strong>, 2014 119<br />

Table 32: <strong>Global</strong> Sales <strong>Forecast</strong>s ($m) for Remicade, 2012-<strong>2022</strong> 120<br />

Table 33: Product Profile - Humira 122<br />

Table 34: Humira Efficacy in the ULTRA 2 Trial 123<br />

Email ID- contact@jsbmarketresearch.com<br />

Tel No- 91 2241236650<br />

Published by- http:/www.jsbmarketresearch.com/

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!